• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Vaccination before and after autologous hematopoietic cell transplantation  for autoimmune diseases: Guidances from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (MATHEC-SFGM-TC)
Bull Cancer. 2023 Jan 17:S0007-4551(22)00426-X. doi: 10.1016/j.bulcan.2022.11.005. Online ahead of print.ABSTRACTThe Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 12th workshop on hematopoietic stem cell transplantation clinical practices harmonization procedures on September 2021 in Lille, France. In the absence of specific national or international recommendation, the French working group for autologous stem Cell transplantation in Auto-immune Diseases (MATHEC) proposed guidances for vaccinations of patients undergoing autologous hematopoietic stem cell transplantation fo...
Source: Bulletin du Cancer - January 19, 2023 Category: Cancer & Oncology Authors: Alexandre Thibault Jacques Maria Arnaud Campidelli Cristina Castilla-Llorente Pauline Lansiaux Zora Marjanovic Gr égory Pugnet Jose Miguel Torregrosa-Diaz Louis Terriou Jean-Pierre Algayres Fanny Urbain Ibrahim Yakoub-Agha Dominique Farge Source Type: research

CAR-T cells development in solid tumors
Bull Cancer. 2022 Dec 19:S0007-4551(22)00436-2. doi: 10.1016/j.bulcan.2022.12.001. Online ahead of print.ABSTRACTCAR-T cells have produced very promising results in the field of onco-hematology and have been rapidly approved for marketing in France for several years now. In solid tumors, current results are more disappointing. Indeed, many hurdles come in the way. Tumor vascularization, the strongly immunosuppressive microenvironment, the loss of the target antigen as well as T cell exhaustion are part of the explanation of those results. Hence many researchers are working to develop strategies to counteract these resistan...
Source: Bulletin du Cancer - December 21, 2022 Category: Cancer & Oncology Authors: Nathan El Ghazzi Antoine Italiano Jacques-Olivier Bay Aurore Doug é Source Type: research

One-month humoral response following two or three doses of mRNA Covid-19 vaccines as primary vaccination in specific populations in France: first results from the ANRS0001S COV-POPART cohort
CONCLUSIONS: Lower COVID-19 vaccine humoral response was observed in specific populations compared to controls. A third dose of vaccine in the primary regimen had a positive effect on both percentages of patients who developed anti-Spike IgG antibodies and specific neutralizing antibodies.PMID:36252789 | DOI:10.1016/j.cmi.2022.10.009
Source: Cancer Control - October 17, 2022 Category: Cancer & Oncology Authors: Paul Loubet Linda Wittkop Laetitia Ninove Mathieu Chalouni Benoit Barrou Jean-Yves Blay Maryvonne Hourmant Eric Thouvenot Martine Laville Bruno Laviolle Jean-Daniel Lelievre Jacques Morel St éphanie Nguyen Quoc Jean-Philippe Spano Benjamin Terrier Anne T Source Type: research

Trajectories and individual determinants of repeated seasonal flu vaccination use over the long term using data from the French E3N cohort
Vaccine. 2022 Jul 18:S0264-410X(22)00855-6. doi: 10.1016/j.vaccine.2022.07.004. Online ahead of print.ABSTRACTDespite the implementation of incentive policies to promote seasonal flu vaccination for more than 20 years in France, the coverage of high-risk individuals remains largely insufficient. While there is extensive literature on the determinants of vaccination in a given year, it rarely considers the specificity of flu vaccination, which must be repeated every autumn to remain effective. We aim to fill this gap by focusing on the flu vaccination behavior of high-risk individuals (65 years and older, chronic diseases) ...
Source: Vaccine - July 21, 2022 Category: Allergy & Immunology Authors: Clara Dugord Carine Franc Source Type: research

Pages: 1  2  3  4